[Federal Register Volume 89, Number 21 (Wednesday, January 31, 2024)]
[Notices]
[Page 6119]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01836]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-D-0361]


Development of Monoclonal Antibody Products Targeting SARS-CoV-2 
for Emergency Use Authorization; Guidance for Industry; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register on December 21, 2023. The 
document announced the availability of a final guidance for industry 
entitled ``Development of Monoclonal Antibody Products Targeting SARS-
CoV-2 for Emergency Use Authorization.'' The document was published 
with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Maria Clary, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 75, Rm. 4638, Silver Spring, MD 20993-0002, 240-
402-8615.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 21, 2023 
(88 FR 88401), in FR Doc. 2023-28092, the following correction is made:
    1. On page 88401, in the first column in the header of the 
document, and in the ADDRESSES section, in the second and third lines 
of the first paragraph, the Docket No. is corrected to read ``Docket 
No. FDA-2024-D-0361.''

    Dated: January 25, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-01836 Filed 1-30-24; 8:45 am]
BILLING CODE 4164-01-P